T-cell Prolymphocytic Leukemia.
MetadataShow full item record
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, cytogenetics, and molecular features. The current therapeutic approach relies on immunotherapy followed by a hematopoietic stem cell transplant in selected cases. Clinical outcomes are generally poor, although insights from genomic and molecular studies may increase our understanding of this disease, with the promise of additional effective therapeutic options.
The Institute of Cancer Research (Grant ID: Unspecified)
Version of record
Hematopoietic Stem Cell Transplantation
Leukemia, Prolymphocytic, T-Cell
License start date
Hematology/oncology clinics of North America, 2017, 31 (2), pp. 273 - 283